---
title: "Biogen Inc. Stock Outperforms Competitors On Strong Trading Day"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292816348.md"
description: "Biogen Inc. (BIIB) shares rose 2.76% to $197.24, outperforming competitors like Johnson & Johnson and Pfizer on a strong trading day. The stock closed 10.23% below its 52-week high, with trading volume of 2.1 million eclipsing the 50-day average."
datetime: "2026-07-15T20:58:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292816348.md)
  - [en](https://longbridge.com/en/news/292816348.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292816348.md)
generator: "portal-rs"
---

# Biogen Inc. Stock Outperforms Competitors On Strong Trading Day

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Biogen Inc. (BIIB) rose 2.76% to $197.24 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index rising 0.38% to 7,572.40 and the Dow Jones Industrial Average rising 0.29% to 52,658.64.

Biogen Inc. closed 10.23% below its 52-week high of $219.72, which the company reached on June 29th.

The stock outperformed some of its competitors Wednesday, as Johnson & Johnson (JNJ) fell 2.69% to $247.02, Pfizer Inc. (PFE) rose 2.35% to $24.82, and AbbVie Inc. (ABBV) rose 0.44% to $244.11.

Trading volume (2.1 M) eclipsed its 50-day average volume of 1.2 M.

Data source: Dow Jones Market Data, FactSet. Data compiled July 15, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

07-15-26 1658ET

### Related Stocks

- [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)

## Related News & Research

- [Biogen And Eisai Announce China Approval For Subcutaneous LEQEMBI To Treat Early Alzheimer's Disease](https://longbridge.com/en/news/297867394.md)
- [Biogen: 4-year Data Support Potential Disease-modifying Effects Of Zorevunersen](https://longbridge.com/en/news/297656275.md)
- [Great Lakes Advisors LLC Takes Position in Biogen Inc. $BIIB](https://longbridge.com/en/news/296676602.md)
- [Biogen platforms lupus patient advocate in social media push](https://longbridge.com/en/news/297335137.md)
- [4,582 Shares in Biogen Inc. $BIIB Purchased by EFG International AG](https://longbridge.com/en/news/297145391.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**